Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
Crossref DOI link: https://doi.org/10.1186/s12962-017-0082-7
Published Online: 2017-09-06
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kousoulakou, Hara
Hatzikou, Magdalini
Baroutsou, Varvara
Yfantopoulos, John
Funding for this research was provided by:
Novartis